Combination therapy doubles one-year survival in pancreatic cancer trial Findings from the randomized trial suggest that modulating the tumour microenvironment alongside chemotherapy may offer a new strategy for improving outcomes in pancreatic cancer Written byBree Foster, PhD

https://www.drugdiscoverynews.com/combination-therapy-doubles-one-year-survival-in-pancreatic-cancer-trial-17121?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9RjxJ5AZAB6xc-u4klI7ipE7m3TNkJzTFeqS9BgF8sKXBfnuZM3YdZDzZ6GCtBHTzDoDxq03B5R8KLzXFyk1NPbXpDhQ&_hsmi=420563864&utm_content=420563864&utm_source=hs_email A drug developed at Northwestern University has shown a promising survival advantage in patients with metastatic pancreatic cancer, a disease that remains among the deadliest solid tumours and is projected to become the second leading cause of cancer-related deaths in the US within the next decade.